Wyeth, Advanced Life In Pact To Develop Antibiotic For Southeast Asia
This article was originally published in PharmAsia News
Wyeth is investing $100 million in a collaboration with Advanced Life Sciences, Holdings, also of the U.S., to develop and market a pneumonia antibiotic for the Asia Pacific region, but excluding Japan. Advanced Life licensed the cethromycin drug from Abbott Laboratories, which has applied for approval in the U.S. and Japan. The drug is one of a class of ketolide antibiotics prescribed to prevent infectious bacteria from becoming resistant to drugs. Advanced Life and Wyeth intend to develop the drug to treat community-acquired pneumonia. (Click here for more
You may also be interested in...
HONG KONG - Wyeth plans to market a second-generation ketolide in the Asia Pacific region, noting that serious side effects associated with the first generation of the new type of antibiotic have not surfaced
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.